Aclaris Therapeutics Inc Cash Flow-to-Debt Ratio
Aclaris Therapeutics Inc cash flow-to-debt ratio. Aclaris Therapeutics Inc (ACRS) has a Cash Flow-to-Debt Ratio of -0.20x as of September 2025, meaning its operating cash flow of $-10.93 Million could theoretically repay 0% of its total liabilities ($55.43 Million) in one year. See ACRS financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aclaris Therapeutics Inc (2013–2024)
Cash flow-to-debt ratio of Aclaris Therapeutics Inc from 2013 to 2024. Historical debt coverage capacity for Aclaris Therapeutics Inc across 12 annual periods. Check ACRS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Aclaris Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2013–2024)
Aclaris Therapeutics Inc cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Aclaris Therapeutics Inc. For the full cash flow conversion analysis, see ACRS cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-20.07 Million | $64.77 Million | ▲ +84.1% |
| 2023 | -1.95x | $-78.33 Million | $40.23 Million | ▼ -64.2% |
| 2022 | -1.19x | $-67.57 Million | $56.98 Million | ▼ -22.5% |
| 2021 | -0.97x | $-52.13 Million | $53.87 Million | ▲ +17.0% |
| 2020 | -1.17x | $-38.63 Million | $33.13 Million | ▲ +65.7% |
| 2019 | -3.40x | $-96.44 Million | $28.39 Million | ▼ -103.7% |
| 2018 | -1.67x | $-100.81 Million | $60.44 Million | ▲ +44.3% |
| 2017 | -3.00x | $-54.66 Million | $18.25 Million | ▲ +42.9% |
| 2016 | -5.25x | $-34.60 Million | $6.59 Million | ▲ +59.9% |
| 2015 | -13.10x | $-20.37 Million | $1.55 Million | ▼ -6441.3% |
| 2014 | -0.20x | $-7.64 Million | $38.13 Million | ▲ +4.9% |
| 2013 | -0.21x | $-4.92 Million | $23.37 Million | — |